Lisa G Spencer is an expert in Pulmonology at Aintree University Hospital (United Kingdom). Lisa G Spencer has authored 83 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 1 of them ongoing. SLR score: 309 (community average: 125). How the SLR is computed.

LeadR Profile

Lisa G Spencer Aintree University Hospital United Kingdom
309 ScienceLeadR Reputation 309
Network Map

Pulmonology

Subspecialties: Rheumatology - Public Health - Critical Care

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2014 - 2026

Source: PubMed

Aintree University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Two lenses, one disease: the power of joint working in SARD-ILD to 'focus' on the best care.
PMID 42312231 — lenses
Rheumatol Adv Pract20260
Outcomes of invasive mechanical ventilation in critically ill patients with interstitial lung disease: protocol for a systematic review and meta-analysis.
PMID 42259559 — lung, fibrosis, pulmonary fibrosis, critical illness, diagnosis, intensive care units, lung diseases, ventilation, vital capacity, lung diseases, interstitial
BMJ Open20260
A statistical Model for Lung Function Trajectory and Mortality in Patients with Fibrotic Interstitial Lung Disease.
PMID 42085272 — bias, mortality, lung, critical care, therapeutics, lung diseases, vital capacity, models, statistical, lung diseases, interstitial
Am J Respir Crit Care Med20260
Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury.
PMID 41581494 — lung, biomedical research, biomarkers, covid-19, matrix metalloproteinases, pulmonary surfactant-associated protein d, infections
EBioMedicine20260
The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-controlled multicentre clinical trial.
PMID 39909521 — idiopathic pulmonary fibrosis, lung, fibrosis, capsules, pulmonary fibrosis, cough, lansoprazole, vital capacity
BMJ Open20250

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 2
Phase 3 2
Phase 4 2
N/A 1
Phase 2/Phase 3 1

By status:

Completed 4
Recruiting 2
Terminated 1
Unknown 1

By type:

Interventional 7
Observational 1

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 0
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 5

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole
NCT04965298 — idiopathic pulmonary fibrosis, lung, stomach, fibrosis, heartburn, multiple chronic conditions, food, spirometry, proton pump inhibitors, signs and symptoms, inosine monophosphate, capsules, pulmonary fibrosis, research, therapeutics, dyspnea, cough, lansoprazole, vital capacity, proton pumps
Phase 3Recruiting2021

LeadR Networks

Main global connection map